olivLaw · US equity research
Entera Bio Ltd. ENTX
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Entera Bio develops oral tablets of peptides and protein therapies, with EB613, an oral bone-building tablet for osteoporosis, as its most advanced candidate. In 2026 the company secured funding for its Phase 3 study through a private placement of roughly 275.0 million USD, after a history of losses and doubts about its ability to continue operating.
At the close of 06 Nov 2026, Entera Bio Ltd. (ENTX) stock was 3.14 USD (+5.02% on the day), with market capitalisation 543.7 m USD, P/E 14.5 on diluted EPS of 0.22 USD over the last 12 months, beta 0.67, 52-week range 1.00–3.92 USD. Latest reported quarter (Q2 2026): revenue of 0 USD, net income of -7.3 m USD, diluted EPS 0.14 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 58.1
- strong (55–70)
- Bollinger (20, 2)
- 2.52 – 3.35
- in the upper half of the band · %B 0.74 · band width 28.1%
- SMA 50 / 200
- 2.88 / 1.94
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.08 / 0.07
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +25.1% | −5.9% | +31.0 pp | — |
| 3 months | +9.4% | −4.6% | +14.0 pp | — |
| 6 months | +141.5% | +0.2% | +141.3 pp | — |
| Year to date | +61.9% | +7.4% | +54.4 pp | — |
| 1 year | +1.0% | +8.2% | −7.2 pp | −8.6% |
| 3 years | +405.6% | +68.4% | +337.2 pp | −12.8% |
| 5 years | −23.4% | +56.5% | −80.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.0 k | 82.0 k | 42.0 k | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 42.0 k | 82.0 k | 42.0 k | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & development | 1.5 m | 1.2 m | 1.1 m | 1.5 m | 1.6 m | 1.7 m | 2.3 m | 3.2 m |
| SG&A | 62.0 k | 96.0 k | 123.0 k | 103.0 k | 122.0 k | 54.0 k | 128.0 k | 124.0 k |
| Operating income | -3.0 m | -2.3 m | -2.6 m | -2.7 m | -3.3 m | -3.0 m | -3.5 m | -4.6 m |
| Pre-tax income | -3.0 m | -2.3 m | — | — | — | — | — | — |
| Income tax | 0 | 14.0 k | — | — | — | — | — | — |
| Net income | -3.0 m | -2.4 m | -2.6 m | -2.7 m | -3.2 m | -3.0 m | -3.5 m | -7.3 m |
| Diluted EPS | 0.08 | -0.06 ≈ | 0.06 | 0.06 | 0.07 | -0.06 ≈ | 0.07 | 0.14 |
| Operating cash flow | -2.2 m ≈ | -1.5 m | -1.4 m | -1.6 m ≈ | -2.5 m ≈ | -1.8 m | -3.1 m | -3.5 m ≈ |
| Capex | 0 ≈ | 3.0 k | 8.0 k | 29.0 k ≈ | 43.0 k ≈ | 27.0 k | 0 | 3.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 72 percentile of its own 18-quarter history (min 3.0, median 10.0, max 16.3; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | ⚠ 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 500.0 k | 236.0 k | 365.0 k | 571.0 k | 134.0 k | 0 | 181.0 k | 42.0 k |
| Revenue YoY | unavailable | −52.8% | — | +56.4% | −76.5% | −100.0% | unavailable | −76.8% |
| Net income | -10.3 m | -10.8 m | -11.2 m | -12.2 m | -13.1 m | -8.9 m | -9.5 m | -11.4 m |
| Net income YoY | unavailable | unavailable | — | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | 1.31 | 0.89 | 0.55 | 0.47 | 0.45 | 0.31 | 0.25 | 0.25 |
| Diluted EPS YoY | −47.4% | −32.1% | — | −14.5% | −4.3% | −31.1% | −19.4% | 0.0% |
| net % | -2,060.8% | -4,574.2% | -3,072.9% | -2,134.3% | -9,754.5% | unavailable | -5,271.3% | -27,235.7% |
| Free cash flow | -9.9 m | -9.0 m | -10.6 m | -9.1 m | -12.5 m | -7.3 m | -6.8 m | -7.5 m |
The series breaks before 2020: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 7.1 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 13.1 m USD
- Total assets
- 16.0 m USD
- Debt / equity
- unavailable
- Current ratio
- 6.94x
- ROE
- -108.0%
- ROA
- -90.1%
- FCF margin
- -17,802.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 365.0 k | 571.0 k | 134.0 k | 0 | 181.0 k | 42.0 k | SEC (XBRL)· 27 Mar 2026verified |
| Cost of revenue | 300.0 k | 373.0 k | 101.0 k | 0 | 172.0 k | 42.0 k | SEC (XBRL)· 27 Mar 2026verified |
| Gross profit | 65.0 k | 198.0 k | 33.0 k | 0 | 9.0 k | 0 | SEC (XBRL)· 27 Mar 2026verified |
| Research & development | 6.4 m | 6.8 m | 5.8 m | 4.5 m | 4.5 m | 6.0 m | SEC (XBRL)· 27 Mar 2026verified |
| SG&A | — | — | — | — | 340.0 k | 398.0 k | SEC (XBRL)· 27 Mar 2026verified |
| Operating income | -11.2 m | -12.2 m | -13.0 m | -8.9 m | -9.6 m | -11.5 m | SEC (XBRL)· 27 Mar 2026verified |
| Depreciation & amortisation | 225.0 k | — | — | — | — | — | SEC (XBRL)· 18 Mar 2021verified |
| EBITDA | -10.9 m ≈ | — | — | — | — | — | SEC (XBRL)· 08 Mar 2022derived |
| Pre-tax income | -11.2 m | -12.2 m | -12.9 m | -8.9 m | -9.5 m | -11.4 m | SEC (XBRL)· 27 Mar 2026verified |
| Income tax | 20.0 k | -59.0 k | 137.0 k | 29.0 k | 14.0 k | 0 | SEC (XBRL)· 27 Mar 2026verified |
| Net income | -11.2 m | -12.2 m | -13.1 m | -8.9 m | -9.5 m | -11.4 m | SEC (XBRL)· 27 Mar 2026verified |
| Diluted EPS | 0.55 | 0.47 | 0.45 | 0.31 | 0.25 | 0.25 | SEC (XBRL)· 27 Mar 2026verified |
| Weighted average diluted shares | 18.6 m | 26.1 m | 28.8 m | 29.0 m | 37.7 m | 46.2 m | SEC (XBRL)· 27 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 8.6 m | 24.9 m | 12.3 m | 11.0 m | 8.7 m | 7.1 m | SEC (XBRL)· 27 Mar 2026verified |
| Receivables | 255.0 k | 183.0 k | 246.0 k | 0 | 126.0 k | 0 | SEC (XBRL)· 27 Mar 2026verified |
| Current assets | 9.1 m | 25.3 m | 12.8 m | 11.3 m | 9.0 m | 15.3 m | SEC (XBRL)· 27 Mar 2026verified |
| Property, plant & equipment, net | 192.0 k | 156.0 k | 139.0 k | 100.0 k | 57.0 k | 134.0 k | SEC (XBRL)· 27 Mar 2026verified |
| Intangibles (excl. goodwill) | 605.0 k | — | — | — | — | — | SEC (XBRL)· 18 Mar 2021verified |
| Total assets | 9.7 m | 26.0 m | 13.1 m | 11.8 m | 9.4 m | 16.0 m | SEC (XBRL)· 27 Mar 2026verified |
| Accounts payable | 164.0 k | 166.0 k | 17.0 k | 83.0 k | 132.0 k | 448.0 k | SEC (XBRL)· 27 Mar 2026verified |
| Current liabilities | 1.8 m | 3.2 m | 1.3 m | 1.1 m | 1.2 m | 2.2 m | SEC (XBRL)· 27 Mar 2026verified |
| Total liabilities | 2.2 m | 3.4 m | 1.4 m | 1.4 m | 1.3 m | 2.9 m | SEC (XBRL)· 27 Mar 2026verified |
| Equity | 6.7 m | 22.6 m † | 11.8 m † | 10.4 m † | 8.1 m † | 13.1 m † | SEC (XBRL)· 27 Mar 2026verified |
| Shares outstanding at year end | 23.7 m | — | — | — | — | — | SEC (XBRL)· 18 Mar 2021verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.6 m | -9.1 m | -12.5 m | -7.3 m | -6.8 m | -7.4 m | SEC (XBRL)· 27 Mar 2026verified |
| Capex | 53.0 k | 17.0 k | 47.0 k | 17.0 k | 3.0 k | 107.0 k | SEC (XBRL)· 27 Mar 2026verified |
| Free cash flow | -10.6 m ≈ | -9.1 m ≈ | -12.5 m ≈ | -7.3 m ≈ | -6.8 m ≈ | -7.5 m ≈ | SEC (XBRL)· 27 Mar 2026derived |
| Investing cash flow | -53.0 k | -17.0 k | -102.0 k | -17.0 k | -3.0 k | -107.0 k | SEC (XBRL)· 27 Mar 2026verified |
| Financing cash flow | 4.1 m | 25.4 m | 13.0 k | 6.0 m | 4.5 m | 13.7 m | SEC (XBRL)· 27 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 39.6% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
06 Nov 2026Source: olivLaw, closing series
Market cap: 543.7 m USD
Key indicators
Coverage and freshness
Score by group
40% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 4.22 – 7.72 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E4.22 – 7.72 (Mid 5.10)4 companies used · median multiple 23.6x · quartiles 19.5x – 35.7xADMA, AMGN, EXEL, TECH
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 39.6% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -32.1% | 0 (on a fixed band) | 21% |
| EPS CAGR 3Y · Growth | -17.8% | 0 (on a fixed band) | 21% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 9.0x | 100 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | 14.5x | 100 (vs peers) | 26% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -2.0% | 0 (on a fixed band) | 21% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation56/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ENTERA BIO LTD. (ENTX). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 42.0 k USD in 2025; YoY growth -76.8%; ROE -138.9%.
The estimated value range is 4.22–7.72 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 5.10 USD, the price of 3.14 USD leaves a potential of 62.6% (value / price − 1) and a margin of safety of 38.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 39.6% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 9.0x
- P/E (TTM): 14.5x
- The price is below the estimated value range
What contradicts it
- Revenue CAGR 3Y: -32.1%
- EPS CAGR 3Y: -17.8%
- FCF yield: -2.0%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Net debt / EBITDA, Interest coverage, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 249.0 bn | 26.7 | 78.4% | 24.1% | +10.0% | +33% / +71% |
| GILDGilead Sciences, Inc. | 207.8 bn | — | -22.3% | -12.5% | +2.4% | +33% / +119% |
| MRNAModerna, Inc. | 96.4 bn | — | -39.0% | -141.4% | −39.9% | +829% / +211% |
| RVMDRevolution Medicines, Inc. | 38.4 bn | — | -93.6% | -946.8% | unavailable | +128% / +661% |
| BIIBBiogen Inc. | 36.1 bn | 104.3 | 1.9% | 3.4% | +2.2% | +34% / +4% |
| EXELExelixis, Inc. | 16.8 bn | 20.5 | 44.3% | 35.5% | +7.0% | +56% / +215% |
| TECHBio-Techne Corp | 11.4 bn | 62.7 | 9.0% | 15.0% | −0.4% | +13% / +16% |
| TWSTTwist Bioscience Corporation | 7.6 bn | — | -29.6% | -31.7% | +20.3% | +277% / +402% |
| SCNIScinai Immunotherapeutics Ltd. | 6.1 bn | — | -91.9% | -633.6% | +99.2% | −96% / −99% |
| SRRKScholar Rock Holding Corporation | 5.7 bn | — | -167.8% | — | unavailable | +7% / +273% |
| ADPTAdaptive Biotechnologies Corporation | 4.5 bn | — | -37.1% | -23.7% | +54.8% | +42% / +539% |
| IOVAIovance Biotherapeutics, Inc. | 3.7 bn | — | -29.1% | -58.2% | +60.6% | +226% / +32% |
| ADMAAdma Biologics, Inc. | 2.8 bn | 16.5 | 41.9% | 35.1% | +19.6% | −34% / +244% |
| VIRVir Biotechnology, Inc. | 2.1 bn | — | -21.8% | -61.0% | −7.6% | +90% / +29% |
| TSHATaysha Gene Therapies, Inc. | 1.4 bn | — | -47.1% | -2,728.0% | +17.3% | −9% / +146% |
| EVAXEvaxion A | 1.3 bn | — | -100.2% | -102.4% | +125.1% | −49% / −92% |
| DNAGinkgo Bioworks Holdings, Inc. | 719.3 m | — | -56.3% | -260.0% | −25.1% | +22% / −78% |
| ATYRaTYR PHARMA INC | 622.9 m | — | -98.4% | -32,003.7% | −19.1% | +713% / +388% |
| FDMT4D Molecular Therapeutics, Inc. | 609.8 m | — | -43.3% | -194.7% | +230,194.6% | +5% / −4% |
| ENTXEntera Bio Ltd. | 543.7 m | 14.5 | -138.9% | — | −76.8% | +1% / +406% |
| RGNXREGENXBIO Inc. | 503.9 m | — | -113.2% | -113.9% | +104.5% | −43% / −61% |
| ALLOAllogene Therapeutics, Inc. | 359.3 m | — | -42.4% | -3,566.7% | −100.0% | −29% / −56% |
| FATEFate Therapeutics Inc | 223.1 m | — | -67.8% | -2,619.6% | −51.2% | +61% / −26% |
| IKTInhibikase Therapeutics, Inc. | 209.3 m | — | -52.0% | — | −100.0% | −1% / +60% |
| ARTVArtiva Biotherapeutics, Inc. | 202.9 m | — | -36.6% | — | −100.0% | +10% / unavailable |
1- and 3-year price returns: for ENTX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Entera Bio develops oral tablets of peptides and protein therapies, with EB613, an oral bone-building tablet for osteoporosis, as its most advanced candidate. In 2026 the company secured funding for its Phase 3 study through a private placement of roughly 275.0 million USD, after a history of losses and doubts about its ability to continue operating.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Going concernhigh
The auditor has expressed substantial doubt about the company's ability to continue operating, and this remains a central risk for investors.
- Funding dependencehigh
The Phase 3 program depends on funding secured in 2026, and any delay could postpone the study.
- Phase 3 outcomehigh
The study with BMD as primary endpoint could fail to confirm efficacy or fail to gain FDA acceptance.
- Dependence on OPKOmedium
The EB612 and EB618 programs depend on the OPKO collaboration, and timelines and cost sharing could change.
- Dilutionmedium
Financing through shares and warrants could significantly dilute existing shareholders.
Investment thesis
What would need to be true (bull case)
- If EB613 shows BMD gains in Phase 3 comparable to injectable treatments, the company could become the first with an oral anabolic for osteoporosis.
- Funding of about 275 million USD could cover the main program through NDA submission and extend the runway into 2030 3.
- The N-Tab platform could generate more programs, and the OPKO collaboration could share costs.
What would break the thesis
- The company has no significant revenue and has accumulated losses over many years, and the auditor has flagged doubt about going concern 1.
- Failure of the Phase 3 study or a rejection of the filing could seriously affect the whole portfolio.
- Dilution from private placements and warrants could reduce the value of existing shares.
What to watch
- Start of the EB613 Phase 3 studylate 2026
- Filing of the EB612 IND applicationfirst half 2027
- Topline results of the EB613 Phase 3 studysecond half 2028
- Update on the funding runway and going concern assessmentnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Net losses were 11.4 million USD in 2025 and 9.5 million USD in 2024, and the accumulated deficit reached 125.4 million USD as of December 31, 2025 1. The independent auditor expressed substantial doubt about the company's ability to continue as a going concern 1. For the quarter ended June 30, 2026, the net loss was 7.3 million USD, partly due to a non-cash remeasurement of 2.7 million USD on pre-funded warrants 3.
After quarter end, the company announced a private placement of about 275.0 million USD led by BVF, intended to fund the EB613 Phase 3 program through NDA submission and extend the cash runway into 2030 3. As of June 30, 2026, cash and cash equivalents were 11.3 million USD and restricted cash, mainly designated for the OPKO collaboration, was 7.1 million USD 3.
Segments
EB618 and oral GLP-2
EB618 is an oral oxyntomodulin analog with dual GLP-1/glucagon action, developed with OPKO for obesity and metabolic disorders, with clinical development to be evaluated after OPKO's Phase 1 studies 13. The oral GLP-2 program targets short bowel syndrome, a rare condition, and is at an early stage 1.
Market context
Osteoporosis is a growing public health issue, causing over two million fractures annually in the United States 1. Total medical costs of osteoporotic fractures are projected to rise from 57 billion USD in 2018 to 95 billion USD by 2040, largely due to population aging 1. Existing anabolic treatments are injectable and used in a minority of very high-risk patients 1.
Short bowel syndrome affects approximately 30,000 patients across the United States and EU, and daily injections create a barrier to adherence 1. The market for hypoparathyroidism is small, but could need oral alternatives if clinical evidence is confirmed 1.
Trends
- BMD qualified as a surrogate endpointtailwind
In December 2025 the FDA qualified total hip BMD as a surrogate efficacy endpoint for fracture, which could speed future studies 1. If the approach holds, study cost and duration could fall.
- Interest in oral peptidestailwind
Oral peptides are attracting attention, and Entera points to the lack of oral treatments for chronic conditions 1. This trend could attract partners and funding.
- Reliance on external fundingheadwind
The company needs additional capital and now depends on the July 2026 placement 13. If funding were delayed, the study timeline could be affected.
- Rising development costsmixed
Research expenses rose in 2026 as the company prepared the Phase 3 study and OPKO activities 3. If this increase continues, losses could remain large.
Competitive position
Entera is compared with injectable anabolic osteoporosis treatments such as Forteo, and with other oral peptides or long-acting injectables for SBS and hypoparathyroidism 1. The source texts also name competitors such as Ascendis Pharma, Zealand Pharma and Ironwood 1.
The company's stated advantage is that an oral tablet could be preferred to daily injections, but this has not been proven commercially 1. Eli Lilly, which markets Forteo, remains an important reference point for EB613 1.
- Eli Lilly (Forteo)LLY
Markets injectable teriparatide, directly compared with EB613 in the company's studies.
- Ascendis Pharma (YORVIPATH)
Daily injectable treatment for hypoparathyroidism, the only approved one named in the source.
- Zealand Pharma
Develops long-acting GLP-2 therapies given by weekly injection for SBS.
- Ironwood
Develops, with Zealand Pharma, GLP-2 therapies given by weekly injection for SBS.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Tranzacție surpriză: Acționarul majoritar al producătorului de mobilă Mobex Târgu Mureș a vândut. Energy Tech Entera preia controlul, după o tranzacție specială de 44 milioane de leiEconomedia · 22 Jun 2026 · RO
- Energy Tech Entera SRL, firmă controlată de acţionarii Plopeanu şi Morariu, a cumpărat pachetul majoritar al lui Mihail Popescu la Mobex pentru 43,8 milioane leiZiarul Financiar · 22 Jun 2026 · RO
The latest news item in our archive is from 22 Jun 2026; the newest SEC filing is from 27 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report27 Oct 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Proxy statement14 Oct 2026
- Current report06 Oct 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report18 Aug 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Quarterly report07 Aug 2026
- Current report07 Aug 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report28 Jul 2026Material agreement · Item 3.02 · Departure or appointment of officers · Financial statements and exhibits
- Current report16 Jul 2026Departure or appointment of officers · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Proxy statement03 Jun 2026
- Quarterly report08 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Entera Bio Ltd. · 27 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Entera Bio Ltd. · 07 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Entera Bio Ltd. · 07 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.